AVBP shareholders elect directors, ratify PwC with 99% support

Q: How many AVBP shares were present at the 2025 Annual Meeting?

A total of 25,159,248 shares, or 73.89% of shares outstanding, were present in person or by proxy.

Q: Were ArriVent BioPharma's director nominees elected in 2025?

Yes. Zhengbin (Bing) Yao, Ph.D. received 22.1 million votes for, and Kristine Peterson received 21.9 million votes for, securing three-year terms.

Q: Did shareholders ratify PwC as AVBP's independent auditor for 2025?

Yes. PricewaterhouseCoopers LLP was ratified with 24,991,469 votes for, representing over 99% approval.

Q: Were there any broker non-votes on the auditor ratification?

No. The auditor ratification item recorded 0 broker non-votes.

Q: Did the 8-K include any financial results or strategic announcements?

No. The report is limited to voting results and contains no financial metrics, guidance, or transaction disclosures.

[8-K] ArriVent BioPharma, Inc. Reports Material Event

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

On June 18, 2025, ArriVent BioPharma, Inc. (Nasdaq: AVBP) convened its 2025 Annual Meeting of Stockholders via live audio webcast. A quorum of 25,159,248 shares (73.89% of the 34,045,193 shares outstanding) was represented.

Key agenda items and results:

Election of Class I Directors (terms expiring 2028)
鈥� Zhengbin (Bing) Yao, Ph.D.: 22,116,332 for / 442,833 withheld / 2,600,083 broker non-votes
鈥� Kristine Peterson: 21,932,842 for / 626,323 withheld / 2,600,083 broker non-votes
Auditor Ratification
PricewaterhouseCoopers LLP re-appointed for the fiscal year ending December 31, 2025 with 24,991,469 for, 242 against and 167,537 abstentions (0 broker non-votes).

No other business was brought before the meeting. The results indicate broad shareholder support for existing governance and the continued engagement of a Big-4 audit firm. No financial guidance, operational updates or strategic transactions were disclosed in this Form 8-K.

Insights

TL;DR: Routine AGM; directors re-elected and PwC ratified with strong majorities鈥攏eutral governance event, minimal immediate valuation impact.

The filing strictly concerns Item 5.07 vote outcomes. Support levels above 97% for both directors and 99% for PwC suggest shareholder satisfaction with board composition and audit oversight. The presence of a 73.9% quorum aligns with typical mid-cap biotech norms, demonstrating adequate investor engagement. Because no compensation or charter amendments were proposed, and no activist resistance surfaced, the event neither enhances nor detracts from the investment thesis. As such, it is viewed as non-impactful on near-term market valuation but confirms stability in governance and audit continuity.

06/20/2025 - 04:14 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2025

ARRIVENT BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41929		86-3336099
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

18 Campus Boulevard, Suite 100

Newtown Square, PA

19073

(Address of principal executive offices)

(zip code)

Registrant’s telephone number, including area code: (628) 277-4836

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		AVBP		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 18, 2025, ArriVent BioPharma, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”) via live audio webcast on the Internet. Of the 34,045,193 shares of common stock, par value $0.0001 per share, issued and outstanding and eligible to vote as of the record date of April 21, 2025, a quorum of 25,159,248 shares, or 73.89% of the eligible shares, was present at the meeting or represented by proxy.

At the Annual Meeting, the stockholders: (1) elected each of Zhengbin (Bing) Yao, Ph.D. and Kristine Peterson to the Company’s board of directors as a Class I director for a term of three years to serve until the 2028 annual meeting of stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation, or removal (“Election of Directors”); and (2) ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 (“Auditor Ratification”). A more complete description of each of these matters is set forth in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 28, 2025.

The number of votes cast in favor or against or withheld by the stockholders and, where applicable, the number of abstentions and the number of broker non-votes on each of the foregoing matters are set forth below.

1. Election of Directors

Nominee

Shares Voted For

Shares Voted to Withhold

Authority

Broker Non-votes

Zhengbin (Bing) Yao, Ph.D.

22,116,332

442,833

2,600,083

Kristine Peterson

21,932,842

626,323

2,600,083

2. Auditor Ratification

Shares Voted For		Shares Voted Against			Shares Abstaining			Broker Non-votes
24,991,469			242			167,537			0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ARRIVENT BIOPHARMA, INC.

	By:	/s/ Winston Kung
		Winston Kung
		Chief Financial Officer and Treasurer

Date: June 20, 2025

Source:

FAQ

How many AVBP shares were present at the 2025 Annual Meeting?

A total of 25,159,248 shares, or 73.89% of shares outstanding, were present in person or by proxy.

Were ArriVent BioPharma's director nominees elected in 2025?

Yes. Zhengbin (Bing) Yao, Ph.D. received 22.1 million votes for, and Kristine Peterson received 21.9 million votes for, securing three-year terms.

Did shareholders ratify PwC as AVBP's independent auditor for 2025?

Yes. PricewaterhouseCoopers LLP was ratified with 24,991,469 votes for, representing over 99% approval.

Were there any broker non-votes on the auditor ratification?

No. The auditor ratification item recorded 0 broker non-votes.

Did the 8-K include any financial results or strategic announcements?

No. The report is limited to voting results and contains no financial metrics, guidance, or transaction disclosures.

AG真人官方

[8-K] ArriVent BioPharma, Inc. Reports Material Event

Insights

FAQ

How many AVBP shares were present at the 2025 Annual Meeting?

Were ArriVent BioPharma's director nominees elected in 2025?

Did shareholders ratify PwC as AVBP's independent auditor for 2025?

Were there any broker non-votes on the auditor ratification?

Did the 8-K include any financial results or strategic announcements?

NASDAQ:AVBP

AVBP Rankings

AVBP Latest News

AVBP Latest SEC Filings

AVBP Stock Data

AG真人官方

Trending News

[8-K] ArriVent BioPharma, Inc. Reports Material Event

Insights

Corporate Governance Analyst neutral

FAQ

How many AVBP shares were present at the 2025 Annual Meeting?

Were ArriVent BioPharma's director nominees elected in 2025?

Did shareholders ratify PwC as AVBP's independent auditor for 2025?

Were there any broker non-votes on the auditor ratification?

Did the 8-K include any financial results or strategic announcements?

NASDAQ:AVBP

AVBP Rankings

AVBP Latest News

AVBP Latest SEC Filings

AVBP Stock Data